Literature DB >> 28939089

Next Steps in the CAR Journey of a Thousand Miles.

Malcolm K Brenner1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28939089      PMCID： PMC5628925          DOI： 10.1016/j.ymthe.2017.09.013

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  8 in total

1.  Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients.

Authors:  H J Kolb; J Mittermüller; C Clemm; E Holler; G Ledderose; G Brehm; M Heim; W Wilmanns
Journal:  Blood       Date:  1990-12-15       Impact factor: 22.113

2.  CARs on track in the clinic.

Authors:  Donald B Kohn; Gianpietro Dotti; Renier Brentjens; Barbara Savoldo; Michael Jensen; Laurence Jn Cooper; Carl H June; Steven Rosenberg; Michel Sadelain; Helen E Heslop
Journal:  Mol Ther       Date:  2011-03       Impact factor: 11.454

3.  T-cell immunotherapy: looking forward.

Authors:  Jacqueline Corrigan-Curay; Hans-Peter Kiem; David Baltimore; Marina O'Reilly; Renier J Brentjens; Laurence Cooper; Stephen Forman; Stephen Gottschalk; Philip Greenberg; Richard Junghans; Helen Heslop; Michael Jensen; Crystal Mackall; Carl June; Oliver Press; Daniel Powell; Antoni Ribas; Steven Rosenberg; Michel Sadelain; Brian Till; Amy P Patterson; Robert C Jambou; Eugene Rosenthal; Linda Gargiulo; Maureen Montgomery; Donald B Kohn
Journal:  Mol Ther       Date:  2014-09       Impact factor: 11.454

4.  Chimeric antigen receptor T cells for sustained remissions in leukemia.

Authors:  Shannon L Maude; Noelle Frey; Pamela A Shaw; Richard Aplenc; David M Barrett; Nancy J Bunin; Anne Chew; Vanessa E Gonzalez; Zhaohui Zheng; Simon F Lacey; Yolanda D Mahnke; Jan J Melenhorst; Susan R Rheingold; Angela Shen; David T Teachey; Bruce L Levine; Carl H June; David L Porter; Stephan A Grupp
Journal:  N Engl J Med       Date:  2014-10-16       Impact factor: 91.245

5.  Graft-versus-leukemia reactions after bone marrow transplantation.

Authors:  M M Horowitz; R P Gale; P M Sondel; J M Goldman; J Kersey; H J Kolb; A A Rimm; O Ringdén; C Rozman; B Speck
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

6.  Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation.

Authors:  E B Papadopoulos; M Ladanyi; D Emanuel; S Mackinnon; F Boulad; M H Carabasi; H Castro-Malaspina; B H Childs; A P Gillio; T N Small
Journal:  N Engl J Med       Date:  1994-04-28       Impact factor: 91.245

7.  Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.

Authors:  Z Eshhar; T Waks; G Gross; D G Schindler
Journal:  Proc Natl Acad Sci U S A       Date:  1993-01-15       Impact factor: 11.205

8.  Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.

Authors:  C M Rooney; C A Smith; C Y Ng; S Loftin; C Li; R A Krance; M K Brenner; H E Heslop
Journal:  Lancet       Date:  1995-01-07       Impact factor: 79.321
  8 in total
  3 in total

1.  Epigenetic Inhibition Puts Target Antigen in the Crosshairs of CAR T Cells.

Authors:  David H M Steffin; Helen E Heslop
Journal:  Mol Ther       Date:  2019-04-18       Impact factor: 11.454

2.  Seek and You Will Not Find: Ending the Hunt for Replication-Competent Retroviruses during Human Gene Therapy.

Authors:  Helen E Heslop; Malcolm K Brenner
Journal:  Mol Ther       Date:  2017-12-20       Impact factor: 11.454

3.  Overcoming Target Driven Fratricide for T Cell Therapy.

Authors:  Eytan Breman; Benjamin Demoulin; Sophie Agaugué; Sebastien Mauën; Alexandre Michaux; Lorraine Springuel; Julien Houssa; Fanny Huberty; Céline Jacques-Hespel; Céline Marchand; Jérôme Marijsse; Thuy Nguyen; Nancy Ramelot; Benjamin Violle; Dorothée Daro; Peter De Waele; David E Gilham; Valérie Steenwinckel
Journal:  Front Immunol       Date:  2018-12-12       Impact factor: 7.561
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.